The DOI matches its Crossref record; 173 of the 173 references it cites were found in a registry or an index.
Alternative splicing in cancer: implications for biology and therapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
The Steroid and Thyroid Hormone Receptor Superfamily
Evans, R. M. (1988) · Science · doi:10.1126/science.3283939 · Cited by 7,439
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1
Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994) · Science · doi:10.1126/science.7545954 · Cited by 6,071
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Identification and characterization of a spinal muscular atrophy-determining gene
Lefebvre, S., Bürglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., Zeviani, M., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90460-3 · Cited by 3,990
Pan, Q., Shai, O., Lee, L. J., Frey, B. J., & Blencowe, B. J. (2008) · Nature Genetics · doi:10.1038/ng.259 · Cited by 3,951
Huggins, C., & Hodges, C. V. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64820-3 · Cited by 3,855
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death
Boise, L. H., González-García, M., Postema, C. E., Ding, L., Lindsten, T., Turka, L. A., Mao, X., Nuñez, G., & Thompson, C. B. (1993) · Cell · doi:10.1016/0092-8674(93)90508-n · Cited by 3,087
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
Christofk, H. R., Vander Heiden, M. G., Harris, M. H., Ramanathan, A., Gerszten, R. E., Wei, R., Fleming, M. D., Schreiber, S. L., & Cantley, L. C. (2008) · Nature · doi:10.1038/nature06734 · Cited by 2,820
The Spliceosome: Design Principles of a Dynamic RNP Machine
Wahl, M. C., Will, C. L., & Lührmann, R. (2009) · Cell · doi:10.1016/j.cell.2009.02.009 · Cited by 2,665
T antigen is bound to a host protein in SY40-transformed cells
LANE, D. P., & CRAWFORD, L. V. (1979) · Nature · doi:10.1038/278261a0 · Cited by 2,394
CD44: From adhesion molecules to signalling regulators
Ponta, H., Sherman, L., & Herrlich, P. A. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1004 · Cited by 2,386
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292
Salzman, J., Gawad, C., Wang, P. L., Lacayo, N., & Brown, P. O. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030733 · Cited by 2,239
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M.-K., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,192
Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6
Yonish-Rouach, E., Resnftzky, D., Lotem, J., Sachs, L., Kimchi, A., & Oren, M. (1991) · Nature · doi:10.1038/352345a0 · Cited by 2,079
Chromosome 17 Deletions and p53 Gene Mutations in Colorectal Carcinomas
Baker, S. J., Fearon, E. R., Nigro, J. M., Hamilton, S. R., Preisinger, A. C., Jessup, J. M., vanTuinen, P., Ledbetter, D. H., Barker, D. F., Nakamura, Y., et al. (1989) · Science · doi:10.1126/science.2649981 · Cited by 2,066
Frequent pathway mutations of splicing machinery in myelodysplasia
Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-Otsubo, A., Kon, A., Nagasaki, M., et al. (2011) · Nature · doi:10.1038/nature10496 · Cited by 2,029
The p53 proto-oncogene can act as a suppressor of transformation
Finlay, C. A., Hinds, P. W., & Levine, A. J. (1989) · Cell · doi:10.1016/0092-8674(89)90045-7 · Cited by 1,987
The first 30 years of p53: growing ever more complex.
Levine, A. J., & Oren, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2723 · Cited by 1,967
Linzer, D. I. H., & Levine, A. J. (1979) · Cell · doi:10.1016/0092-8674(79)90293-9 · Cited by 1,813
Meta-Analysis of BRCA1 and BRCA2 Penetrance
Chen, S., & Parmigiani, G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.1066 · Cited by 1,802
The p53-mdm-2 autoregulatory feedback loop.
Wu, X., Bayle, J. H., Olson, D., & Levine, A. J. (1993) · Genes & Development · doi:10.1101/gad.7.7a.1126 · Cited by 1,801
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771
hnRNP PROTEINS AND THE BIOGENESIS OF mRNA
Dreyfuss, G., Matunis, M. J., Pinol-Roma, S., & Burd, C. G. (1993) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.62.070193.001445 · Cited by 1,560
In vivo amplification of the androgen receptor gene and progression of human prostate cancer
Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinänen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., & Kallioniemi, O.-P. (1995) · Nature Genetics · doi:10.1038/ng0495-401 · Cited by 1,484
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454
Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53
Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., & Vogelstein, B. (1993) · Nature · doi:10.1038/362857a0 · Cited by 1,451
Understanding alternative splicing: towards a cellular code
Matlin, A. J., Clark, F., & Smith, C. W. J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1645 · Cited by 1,305
Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches
Chen, M., & Manley, J. L. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2777 · Cited by 1,284
HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer
David, C. J., Chen, M., Assanah, M., Canoll, P., & Manley, J. L. (2010) · Nature · doi:10.1038/nature08697 · Cited by 1,179
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
Wilson, T. R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., Peng, J., Lin, E., Wang, Y., Sosman, J., et al. (2012) · Nature · doi:10.1038/nature11249 · Cited by 1,134
When mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132
Protection from Fas-Mediated Apoptosis by a Soluble Form of the Fas Molecule
Cheng, J., Zhou, T., Liu, C., Shapiro, J. P., Brauer, M. J., Kiefer, M. C., Barr, P. J., & Mountz, J. D. (1994) · Science · doi:10.1126/science.7510905 · Cited by 1,107
Alternative splicing and evolution: diversification, exon definition and function
Keren, H., Lev-Maor, G., & Ast, G. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2776 · Cited by 1,082
Hu, R., Dunn, T. A., Wei, S., Isharwal, S., Veltri, R. W., Humphreys, E., Han, M., Partin, A. W., Vessella, R. L., Isaacs, W. B., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2764 · Cited by 1,077
Predictive Identification of Exonic Splicing Enhancers in Human Genes
Fairbrother, W. G., Yeh, R.-F., Sharp, P. A., & Burge, C. B. (2002) · Science · doi:10.1126/science.1073774 · Cited by 1,036
The gene encoding the splicing factor SF2/ASF is a proto-oncogene
Karni, R., de Stanchina, E., Lowe, S. W., Sinha, R., Mu, D., & Krainer, A. R. (2007) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1209 · Cited by 934
A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage
Tanaka, H., Arakawa, H., Yamaguchi, T., Shiraishi, K., Fukuda, S., Matsui, K., Takei, Y., & Nakamura, Y. (2000) · Nature · doi:10.1038/35003506 · Cited by 904
Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage
Scully, R., Chen, J., Ochs, R. L., Keegan, K., Hoekstra, M., Feunteun, J., & Livingston, D. M. (1997) · Cell · doi:10.1016/s0092-8674(00)80503-6 · Cited by 900
Self-citationComprehensive proteomic analysis of the human spliceosome
Zhou, Z., Licklider, L. J., Gygi, S. P., & Reed, R. (2002) · Nature · doi:10.1038/nature01031 · Cited by 893
Guo, Z., Yang, X., Sun, F., Jiang, R., Linn, D. E., Chen, H., Chen, H., Kong, X., Melamed, J., Tepper, C. G., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3795 · Cited by 880
Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line.
Shaw, P., Bovey, R., Tardy, S., Sahli, R., Sordat, B., & Costa, J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4495 · Cited by 848
Dehm, S. M., Schmidt, L. J., Heemers, H. V., Vessella, R. L., & Tindall, D. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0594 · Cited by 834
Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged
David, C. J., & Manley, J. L. (2010) · Genes & Development · doi:10.1101/gad.1973010 · Cited by 814
Pyruvate kinase type M2 and its role in tumor growth and spreading
Mazurek, S., Boschek, C. B., Hugo, F., & Eigenbrodt, E. (2005) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.04.009 · Cited by 812
p53 isoforms can regulate p53 transcriptional activity
Bourdon, J.-C., Fernandes, K., Murray-Zmijewski, F., Liu, G., Diot, A., Xirodimas, D. P., Saville, M. K., & Lane, D. P. (2005) · Genes & Development · doi:10.1101/gad.1339905 · Cited by 810
Presence of a Potent Transcription Activating Sequence in the p53 Protein
Fields, S., & Jang, S. K. (1990) · Science · doi:10.1126/science.2144363 · Cited by 790
Inactivation of the SR Protein Splicing Factor ASF/SF2 Results in Genomic Instability
Li, X., & Manley, J. L. (2005) · Cell · doi:10.1016/j.cell.2005.06.008 · Cited by 769
Wu, J. Y., & Maniatis, T. (1993) · Cell · doi:10.1016/0092-8674(93)90316-i · Cited by 750
Sun, S., Sprenger, C. C. T., Vessella, R. L., Haugk, K., Soriano, K., Mostaghel, E. A., Page, S. T., Coleman, I. M., Nguyen, H. M., Sun, H., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41824 · Cited by 748
Identification of a RING protein that can interact in vivo with the BRCA1 gene product
Wu, L. C., Wang, Z. W., Tsan, J. T., Spillman, M. A., Phung, A., Xu, X. L., Yang, M.-C. W., Hwang, L.-Y., Bowcock, A. M., & Baer, R. (1996) · Nature Genetics · doi:10.1038/ng1296-430 · Cited by 746
Hua, Y., Sahashi, K., Rigo, F., Hung, G., Horev, G., Bennett, C. F., & Krainer, A. R. (2011) · Nature · doi:10.1038/nature10485 · Cited by 741
Functional consequences of developmentally regulated alternative splicing
Kalsotra, A., & Cooper, T. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg3052 · Cited by 729
Huggins, C., & Hodges, C. V. (2002) · Journal of Urology · doi:10.1016/s0022-5347(02)80307-x · Cited by 716
Formation of the Androgen Receptor Transcription Complex
Shang, Y., Myers, M., & Brown, M. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00471-9 · Cited by 672
SR proteins and splicing control.
Manley, J. L., & Tacke, R. (1996) · Genes & Development · doi:10.1101/gad.10.13.1569 · Cited by 671
Splicing factor SF3b as a target of the antitumor natural product pladienolide
Kotake, Y., Sagane, K., Owa, T., Mimori-Kiyosue, Y., Shimizu, H., Uesugi, M., Ishihama, Y., Iwata, M., & Mizui, Y. (2007) · Nature Chemical Biology · doi:10.1038/nchembio.2007.16 · Cited by 657
Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA
Kaida, D., Motoyoshi, H., Tashiro, E., Nojima, T., Hagiwara, M., Ishigami, K., Watanabe, H., Kitahara, T., Yoshida, T., Nakajima, H., et al. (2007) · Nature Chemical Biology · doi:10.1038/nchembio.2007.18 · Cited by 650
Watson, P. A., Chen, Y. F., Balbas, M. D., Wongvipat, J., Socci, N. D., Viale, A., Kim, K., & Sawyers, C. L. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012443107 · Cited by 639
Transcriptional Activation by Wild-Type but Not Transforming Mutants of the p53 Anti-Oncogene
Raycroft, L., Wu, H., & Lozano, G. (1990) · Science · doi:10.1126/science.2144364 · Cited by 619
Structural Evidence for Ligand Specificity in the Binding Domain of the Human Androgen Receptor
Matias, P. M., Donner, P., Coelho, R., Thomaz, M., Peixoto, C., Macedo, S., Otto, N., Joschko, S., Scholz, P., Wegg, A., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004571200 · Cited by 608
Noguchi, T., Inoue, H., & Tanaka, T. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)67091-7 · Cited by 537
20 Splicing of Precursors to mRNAs by the Spliceosomes
Burge, C. B., Tuschl, T., & Sharp, P. A. (1999) · doi:10.1101/087969589.37.525 · Cited by 534
Distinct p53 Transcriptional Programs Dictate Acute DNA-Damage Responses and Tumor Suppression
Brady, C. A., Jiang, D., Mello, S. S., Johnson, T. M., Jarvis, L. A., Kozak, M. M., Broz, D. K., Basak, S., Park, E. J., McLaughlin, M. E., et al. (2011) · Cell · doi:10.1016/j.cell.2011.03.035 · Cited by 533
Jenster, G., van der Korput, H. A. G. M., van Vroonhoven, C., van der Kwast, T. H., Trapman, J., & Brinkmann, A. O. (1991) · Molecular Endocrinology · doi:10.1210/mend-5-10-1396 · Cited by 523
Murray-Zmijewski, F., Lane, D. P., & Bourdon, J.-C. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401914 · Cited by 523
Identification of functional exonic splicing enhancer motifs recognized by individual SR proteins
Liu, H.-X., Zhang, M., & Krainer, A. R. (1998) · Genes & Development · doi:10.1101/gad.12.13.1998 · Cited by 510
Lubahn, D. B., Brown, T. R., Simental, J. A., Higgs, H. N., Migeon, C. J., Wilson, E. M., & French, F. S. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.23.9534 · Cited by 452
Tissue-specific alternative splicing remodels protein-protein interaction networks
Ellis, J. D., Barrios-Rodiles, M., Çolak, R., Irimia, M., Kim, T., Calarco, J. A., Wang, X., Pan, Q., O'Hanlon, D., Kim, P. M., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.05.037 · Cited by 431
The spliceosome as a target of novel antitumour drugs
Bonnal, S., Vigevani, L., & Valcárcel, J. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3823 · Cited by 405
Structural basis of androgen receptor binding to selective androgen response elements
Shaffer, P. L., Jivan, A., Dollins, D. E., Claessens, F., & Gewirth, D. T. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401123101 · Cited by 400
Cascino, I., Fiucci, G., Papoff, G., & Ruberti, G. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.6.2706 · Cited by 397
Molecular basis of androgen insensitivity
Brinkmann, A. O. (2001) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(01)00466-x · Cited by 348
Cancer-associated regulation of alternative splicing
Venables, J. P., Klinck, R., Koh, C., Gervais-Bird, J., Bramard, A., Inkel, L., Durand, M., Couture, S., Froehlich, U., Lapointe, E., et al. (2009) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1608 · Cited by 342
p53 isoforms Δ133p53 and p53β are endogenous regulators of replicative cellular senescence
Fujita, K., Mondal, A. M., Horikawa, I., Nguyen, G. H., Kumamoto, K., Sohn, J. J., Bowman, E. D., Mathe, E. A., Schetter, A. J., Pine, S. R., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1928 · Cited by 336
Splicing with inverted order of exons occurs proximal to large introns.
Cocquerelle, C., Daubersies, P., Majérus, M. A., Kerckaert, J. P., & Bailleul, B. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05148.x · Cited by 314
Integrative genomics identifies LMO1 as a neuroblastoma oncogene
Wang, K., Diskin, S. J., Zhang, H., Attiyeh, E. F., Winter, C., Hou, C., Schnepp, R. W., Diamond, M., Bosse, K., Mayes, P. A., et al. (2011) · Nature · doi:10.1038/nature09609 · Cited by 310
Starving the Addiction: New Opportunities for Durable Suppression of AR Signaling in Prostate Cancer
Knudsen, K. E., & Scher, H. I. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2660 · Cited by 307
Common variations in BARD1 influence susceptibility to high-risk neuroblastoma
Capasso, M., Devoto, M., Hou, C., Asgharzadeh, S., Glessner, J. T., Attiyeh, E. F., Mosse, Y. P., Kim, C., Diskin, S. J., Cole, K. A., et al. (2009) · Nature Genetics · doi:10.1038/ng.374 · Cited by 305
Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene.
Matlashewski, G., Lamb, P., Pim, D., Peacock, J., Crawford, L., & Benchimol, S. (1984) · The EMBO Journal · doi:10.1002/j.1460-2075.1984.tb02287.x · Cited by 299
RESCUE-ESE identifies candidate exonic splicing enhancers in vertebrate exons
Fairbrother, W. G., Yeo, G. W., Yeh, R., Goldstein, P., Mawson, M., Sharp, P. A., & Burge, C. B. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh393 · Cited by 289
Tepper, C. G., Boucher, D. L., Ryan, P. E., Ma, A., Xia, L. P., Lee, L., Pretlow, T. G., & Kung, H.-J. (2002) · PubMed · Cited by 265
Courtois, S., Verhaegh, G., North, S., Luciani, M.-G., Lassus, P., Hibner, U., Oren, M., & Hainaut, P. (2002) · Oncogene · doi:10.1038/sj.onc.1205874 · Cited by 263
Corrionero, A., Miñana, B., & Valcárcel, J. (2011) · Genes & Development · doi:10.1101/gad.2014311 · Cited by 263
Expression and Role of Bcl–Xl in Human Hepatocellular Carcinomas
Takehara, T., Liu, X., Fujimoto, J., Friedman, S. L., & Takahashi, H. (2001) · Hepatology · doi:10.1053/jhep.2001.25387 · Cited by 246
Alternative Splicing in Colon, Bladder, and Prostate Cancer Identified by Exon Array Analysis
Thorsen, K., Sørensen, K. D., Brems-Eskildsen, A. S., Modin, C., Gaustadnes, M., Hein, A.-M. K., Kruhøffer, M., Laurberg, S., Borre, M., Wang, K., et al. (2008) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m700590-mcp200 · Cited by 245
Exonic Splicing Enhancer Motif Recognized by Human SC35 under Splicing Conditions
Liu, H.-X., Chew, S. L., Cartegni, L., Zhang, M. Q., & Krainer, A. R. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.3.1063-1071.2000 · Cited by 244
Mayeda, A., Helfman, D. M., & Krainer, A. R. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.5.2993 · Cited by 242
Androgen Receptor Variants Occur Frequently in Castration Resistant Prostate Cancer Metastases
Zhang, X., Morrissey, C., Sun, S., Ketchandji, M., Nelson, P. S., True, L. D., Vakar-Lopez, F., Vessella, R. L., & Plymate, S. R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027970 · Cited by 240
Identification of a New Class of Exonic Splicing Enhancers by In Vivo Selection
Coulter, L. R., Landree, M. A., & Cooper, T. A. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.4.2143 · Cited by 236
Variation in sequence and organization of splicing regulatory elements in vertebrate genes
Yeo, G., Hoon, S., Venkatesh, B., & Burge, C. B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404901101 · Cited by 230
Regulation of Human p53 Activity and Cell Localization by Alternative Splicing
Ghosh, A., Stewart, D., & Matlashewski, G. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.18.7987-7997.2004 · Cited by 221
Chan, S. C., Li, Y., & Dehm, S. M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.352930 · Cited by 218
Spinal muscular atrophy: mechanisms and therapeutic strategies
Lorson, C. L., Rindt, H., & Shababi, M. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq147 · Cited by 209
Two internal ribosome entry sites mediate the translation of p53 isoforms
Ray, P. S., Grover, R., & Das, S. (2006) · EMBO reports · doi:10.1038/sj.embor.7400623 · Cited by 208
Hu, R., Isaacs, W. B., & Luo, J. (2011) · The Prostate · doi:10.1002/pros.21382 · Cited by 207
Regulation of CD44 Alternative Splicing by SRm160 and Its Potential Role in Tumor Cell Invasion
Cheng, C., & Sharp, P. A. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.1.362-370.2006 · Cited by 201
Drug Insight: role of the androgen receptor in the development and progression of prostate cancer
Taplin, M.-E. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0765 · Cited by 197
CD95, BIM and T cell homeostasis
Bouillet, P., & O'Reilly, L. A. (2009) · Nature Reviews Immunology · doi:10.1038/nri2570 · Cited by 190
Wu, J. Q., Habegger, L., Noisa, P., Szekely, A., Qiu, C., Hutchison, S., Raha, D., Egholm, M., Lin, H., Weissman, S., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914114107 · Cited by 189
Thai, T. (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.2.195 · Cited by 185
Intron Size, Abundance, and Distribution within Untranslated Regions of Genes
Hong, X., Scofield, D. G., & Lynch, M. (2006) · Molecular Biology and Evolution · doi:10.1093/molbev/msl111 · Cited by 184
Xu, Q. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg786 · Cited by 176
NAKAJIMA, H., SATO, B., FUJITA, T., TAKASE, S., TERANO, H., & OKUHARA, M. (1996) · The Journal of Antibiotics · doi:10.7164/antibiotics.49.1196 · Cited by 174
Attard, G., Reid, A. H. M., Olmos, D., & de Bono, J. S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4531 · Cited by 168
Sudemycins, Novel Small Molecule Analogues of FR901464, Induce Alternative Gene Splicing
Fan, L., Lagisetti, C., Edwards, C. C., Webb, T. R., & Potter, P. M. (2011) · ACS Chemical Biology · doi:10.1021/cb100356k · Cited by 167
Tang, Y., Horikawa, I., Ajiro, M., Robles, A. I., Fujita, K., Mondal, A. M., Stauffer, J. K., Zheng, Z.-M., & Harris, C. C. (2013) · Oncogene · doi:10.1038/onc.2012.288 · Cited by 165
Babic, I., Anderson, E. S., Tanaka, K., Guo, D., Masui, K., Li, B., Zhu, S., Gu, Y., Villa, G. R., Akhavan, D., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.013 · Cited by 164
Folco, E. G., Coil, K. E., & Reed, R. (2011) · Genes & Development · doi:10.1101/gad.2009411 · Cited by 162
Splicing factor hnRNPH drives an oncogenic splicing switch in gliomas
LeFave, C. V., Squatrito, M., Vorlová, S., Rocco, G., Brennan, C., Holland, E. C., Pan, Y., & Cartegni, L. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.259 · Cited by 160
Intronic splicing enhancers, cognate splicing factors and context-dependent regulation rules
Wang, Y., Ma, M., Xiao, X., & Wang, Z. (2012) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2377 · Cited by 160
Discovery and Analysis of Evolutionarily Conserved Intronic Splicing Regulatory Elements
Yeo, G. W., Nostrand, E. L. V., & Liang, T. Y. (2007) · PLoS Genetics · doi:10.1371/journal.pgen.0030085 · Cited by 160
Chen, J., Ng, S. M., Chang, C., Zhang, Z., Bourdon, J.-C., Lane, D. P., & Peng, J. (2009) · Genes & Development · doi:10.1101/gad.1761609 · Cited by 154
Self-citationThe role of U2AF35 and U2AF65 in enhancer-dependent splicing
Graveley, B. R., Hertel, K. J., & Maniatis, T. (2001) · RNA · doi:10.1017/s1355838201010317 · Cited by 151
McCarthy, E. E., Celebi, J. T., Baer, R. J., & Ludwig, T. E. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.14.5056-5063.2003 · Cited by 140
Avery‐Kiejda, K. A., Zhang, X. D., Adams, L. J., Scott, R. J., Vojtěšek, B., Lane, D. P., & Hersey, P. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1422 · Cited by 138
SAKAI, T., Sameshima, T., Matsufuji, M., Kawamura, N., Dobashi, K., & Mizui, Y. (2004) · The Journal of Antibiotics · doi:10.7164/antibiotics.57.173 · Cited by 131
Candeias, M. M., Powell, D. J., Roubalová, E., Apcher, S., Bourougaa, K., Vojtěšek, B., Bruzzoni‐Giovanelli, H., & Fåhræus, R. (2006) · Oncogene · doi:10.1038/sj.onc.1209996 · Cited by 129
Evidence for Calpain-Mediated Androgen Receptor Cleavage as a Mechanism for Androgen Independence
Libertini, S. J., Tepper, C. G., Rodriguez, V., Asmuth, D. M., Kung, H.-J., & Mudryj, M. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1072 · Cited by 129
Immunologically Distinct p53 Molecules Generated by Alternative Splicing
Arai, N., Nomura, D., Yokota, K., Wolf, D., Brill, E., Shohat, O., & Rotter, V. (1986) · Molecular and Cellular Biology · doi:10.1128/mcb.6.9.3232 · Cited by 128
The splicing-factor oncoprotein SF2/ASF activates mTORC1
Karni, R., Hippo, Y., Lowe, S. W., & Krainer, A. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801376105 · Cited by 125
Is there more to BARD1 than BRCA1?
Irminger‐Finger, I., & Jefford, C. E. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1878 · Cited by 125
Δ160p53 is a novel N‐terminal p53 isoform encoded by Δ133p53 transcript
Marcel, V., Perrier, S., Aoubala, M., Ageorges, S., Groves, M. J., Diot, A., Fernandes, K., Tauro, S., & Bourdon, J.-C. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.10.005 · Cited by 125
Androgen receptor function is modulated by the tissue-specific AR45 variant
Ahrens‐Fath, I., Politz, O., Geserick, C., & Haendler, B. (2004) · FEBS Journal · doi:10.1111/j.1432-1033.2004.04395.x · Cited by 119
Identification of BARD1 as Mediator between Proapoptotic Stress and p53-Dependent Apoptosis
Irminger‐Finger, I., Leung, W., Li, J., Dubois‐Dauphin, M., Harb, J., Féki, A., Jefford, C. E., Soriano, J. V., Jaconi, M. E., Montesano, R., et al. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00406-3 · Cited by 118
Capasso, M., Diskin, S. J., Totaro, F., Longo, L., Mariano, M. D., Russo, R., Cimmino, F., Hakonarson, H. H., Tonini, G. P., Devoto, M., et al. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs380 · Cited by 115
Ghimenti, C., Sensi, E., Presciuttini, S., Brunetti, I. M., Conte, P., Bevilacqua, G., & Caligo, M. A. (2002) · Genes Chromosomes and Cancer · doi:10.1002/gcc.1223 · Cited by 110
Bourdon, J., Khoury, M. P., Diot, A., Baker, L., Fernandes, K., Aoubala, M., Quinlan, P., Purdie, C. A., Jordan, L. B., Prats, A., et al. (2011) · Breast Cancer Research · doi:10.1186/bcr2811 · Cited by 110
Webb, T. R., Joyner, A. S., & Potter, P. M. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.07.013 · Cited by 105
Marcias, G., Erdmann, É., Lapouge, G., Siebert, C., Barthélémy, P., Duclos, B., Bergerat, J., Céraline, J., & Kurtz, J. (2009) · Human Mutation · doi:10.1002/humu.21138 · Cited by 105
Blockade of Fas-dependent apoptosis by soluble Fas in LGL leukemia
Liu, J. H., Wei, S., Lamy, T., Li, Y., Epling‐Burnette, P. K., Djeu, J. Y., & Loughran, T. P. (2002) · Blood · doi:10.1182/blood.v100.4.1449.h81602001449_1449_1453 · Cited by 102
Wang, Y., Blandino, G., Oren, M., & Givol, D. (1998) · Oncogene · doi:10.1038/sj.onc.1202113 · Cited by 102
Cappellari, M., Bielli, P., Paronetto, M. P., Ciccosanti, F., Fimia, G. M., Saarikettu, J., Silvennoinen, O., & Sette, C. (2013) · Oncogene · doi:10.1038/onc.2013.360 · Cited by 99
Karppinen, S., Heikkinen, K., Rapakko, K., & Winqvist, R. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2004.020669 · Cited by 98
The human tumour suppressor gene p53 is alternatively spliced in normal cells.
Flaman, J., Waridel, F., Estreicher, A., Vannier, A., Limacher, J., Gilbert, D., Iggo, R. D., & Frébourg, T. (1996) · PubMed · Cited by 98
Irminger‐Finger, I., Soriano, J. V., Vaudan, G., Montesano, R., & Sappino, A. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.143.5.1329 · Cited by 97
Bosse, K. R., Diskin, S. J., Cole, K. A., Wood, A., Schnepp, R. W., Norris, G. T., Nguyễn, L. B., Jagannathan, J., LaQuaglia, M. P., Winter, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3703 · Cited by 97
Predominant expression of the long isoform of Bcl‐x (Bcl‐xL) in human lymphomas
Xerri, L., Parc, P., Brousset, P., Schlaifer, D., Hassoun, J., Reed, J. C., Krajewski, S., & Birnbaum, D. (1996) · British Journal of Haematology · doi:10.1046/j.1365-2141.1996.423958.x · Cited by 94
DEGRADE, MOVE, REGROUP: signaling control of splicing proteins
Heyd, F., & Lynch, K. W. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2011.04.003 · Cited by 90
BARD1 induces apoptosis by catalysing phosphorylation of p53 by DNA-damage response kinase
Féki, A., Jefford, C. E., Berardi, P., Wu, J., Cartier, L., Krause, K., & Irminger‐Finger, I. (2005) · Oncogene · doi:10.1038/sj.onc.1208491 · Cited by 85
Jagla, M., Fève, M., Kessler, P., Lapouge, G., Erdmann, É., Serra, S., Bergerat, J., & Céraline, J. (2007) · Endocrinology · doi:10.1210/en.2007-0446 · Cited by 83
Hofstetter, G., Berger, A., Fiegl, H., Slade, N., Zorić, A., Holzer, B., Schuster, E., Möbus, V. J., Reimer, D., Daxenbichler, G., et al. (2010) · Oncogene · doi:10.1038/onc.2009.482 · Cited by 82
Ghigna, C., Moroni, M., Porta, C., Riva, S., & Biamonti, G. (1998) · PubMed · Cited by 80
Marcel, V., Vijayakumar, V., Fernandez‐Cuesta, L., Hafsi, H., Sagne, C., Hautefeuille, A. H., Olivier, M., & Hainaut, P. L. (2010) · Oncogene · doi:10.1038/onc.2010.26 · Cited by 79
Ryser, S., Dizin, É., Jefford, C. E., Delaval, B., Gagos, S., Christodoulidou, A., Krause, K., Birnbaum, D., & Irminger‐Finger, I. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2134 · Cited by 74
Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosis
Wu, J., Vlastos, A., Pelte, M., Caligo, M. A., Bianco, A., Krause, K., Laurent, G. J., & Irminger‐Finger, I. (2005) · International Journal of Cancer · doi:10.1002/ijc.21428 · Cited by 74
Hui, L., Zhang, X., Wu, X., Lin, Z., Wang, Q., Li, Y., & Hu, G. (2004) · Oncogene · doi:10.1038/sj.onc.1207362 · Cited by 68
Spliceostatin A blocks angiogenesis by inhibiting global gene expression including VEGF
Furumai, R., Uchida, K., Komi, Y., Yoneyama, M., Ishigami, K., Watanabe, H., Kojima, S., & Yoshida, M. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01686.x · Cited by 66
Oncogenic BARD1 Isoforms Expressed in Gynecological Cancers
Li, L., Ryser, S., Dizin, É., Pils, D., Krainer, M., Jefford, C. E., Bertoni, F., Zeillinger, R., & Irminger‐Finger, I. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2370 · Cited by 65
Crawford, J. B., & Patton, J. G. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.01677-06 · Cited by 58
Nuclear–cytoplasmic translocation of BARD1 is linked to its apoptotic activity
水野, 晴., 塚越, 康., Harb, J., 田中, 詳., & 大澤, 潔. (2004) · Oncogene · doi:10.1038/sj.onc.1207427 · Cited by 57
Hafsi, H., Santos‐Silva, D., Courtois-Cox, S., & Hainaut, P. L. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-134 · Cited by 56
Piekiełko‐Witkowska, A., Wiszomirska, H., Wójcicka, A., Popławski, P., Bogusławska, J., Tański, Z., & Nauman, A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013690 · Cited by 54
Ris‐Stalpers, C., Verleun-Mooijman, M. C. T., de Blaeij, T. J., DEGENHART, H. J., Trapman, J., & Brinkmann, A. O. (1994) · PubMed Central · Cited by 51
BARD1: An independent predictor of survival in non‐small cell lung cancer
Zhang, Y., Bianco, A., Malkinson, A. M., Leoni, V. P., Frau, G., Rosa, N. D., André, P., Versace, R., Boulvain, M., Laurent, G. J., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26346 · Cited by 51
Circulating Soluble Fas in Patients with Breast Cancer
Sheen‐Chen, S., Chen, H., Eng, H., & Chen, W. (2003) · World Journal of Surgery · doi:10.1007/s00268-002-6378-5 · Cited by 48
Guo, X. Y., Chen, Q., Song, Y. K., Wei, J. S., & Khan, J. I. (2011) · BMC Medical Genomics · doi:10.1186/1755-8794-4-35 · Cited by 48
Brüggenwirth, H. T., Boehmer, A. L. M., Ramnarain, S., Verleun-Mooijman, M. C. T., Satijn, D. P. E., Trapman, J., Grootegoed, J. A., & Brinkmann, A. O. (1997) · The American Journal of Human Genetics · doi:10.1086/301605 · Cited by 47
Dizin, É., & Irminger‐Finger, I. (2010) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2009.12.025 · Cited by 45
BARD1 Expression Predicts Outcome in Colon Cancer
Sporn, J. C., Hothorn, T., & Jung, B. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0263 · Cited by 43
Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancer
Marabese, M., Marchini, S., Marrazzo, E., Mariani, P., Cattaneo, D., Fossati, R., Compagnoni, A., Signorelli, M., Moll, U. M., Codegoni, A. M., et al. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.10.011 · Cited by 37
Zhang, Y.-Q., Pilyugin, M., Kuester, D., Leoni, V. P., Li, L., Casula, G., Zorcolo, L., Schneider‐Stock, R., Atzori, L., & Irminger‐Finger, I. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.297 · Cited by 34
Hellwinkel, O., Holterhus, P., Struve, D., Marschke, C., Homburg, N., & Hiort, O. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.6.7543 · Cited by 33
A truncated splice variant of human BARD1 that lacks the RING finger and ankyrin repeats
Tsuzuki, M., Wu, W., Nishikawa, H., Hayami, R., Oyake, D., Yabuki, Y., Fukuda, M., & Ohta, T. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.03.012 · Cited by 32
Alternative splicing of human p53 transcripts.
Matlashewski, G., Pim, D., Banks, L. T., & Crawford, L. (1987) · PubMed · Cited by 30
Hellwinkel, O., Bull, K., Holterhus, P., Homburg, N., Struve, D., & Hiort, O. (1999) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(98)00157-5 · Cited by 29
Ikonen, T., Palvimo, J. J., & Jänne, O. A. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)00701-7 · Cited by 28
Lim, J. T. S., Ghadessy, F. J., & Yong, E. (1997) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(97)00109-3 · Cited by 24
Cited by
Translating RNA sequencing into clinical diagnostics: opportunities and challenges
Byron, S. A., Van Keuren-Jensen, K. R., Engelthaler, D. M., Carpten, J. D., & Craig, D. W. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.10 · Cited by 809
PKM2, function and expression and regulation
Zhang, Z., Deng, X., Liu, Y., Liu, Y., Sun, L., & Chen, F. (2019) · Cell & Bioscience · doi:10.1186/s13578-019-0317-8 · Cited by 498
Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes
Sveen, A., Kilpinen, S., Ruusulehto, A., Lothe, R. A., & Skotheim, R. I. (2016) · Oncogene · doi:10.1038/onc.2015.318 · Cited by 470
Tardaguila, M., de la Fuente, L., Marti, C., Pereira, C., Pardo-Palacios, F. J., del Risco, H., Ferrell, M., Mellado, M., Macchietto, M., Verheggen, K., et al. (2018) · Genome Research · doi:10.1101/gr.222976.117 · Cited by 454
The functional diversity of Aurora kinases: a comprehensive review
Willems, E., Dedobbeleer, M., Digregorio, M., Lombard, A., Lumapat, P. N., & Rogister, B. (2018) · Cell Division · doi:10.1186/s13008-018-0040-6 · Cited by 416
Metadata
- Authors
- Chen, J., & Weiss, W. A.
- Venue
- Oncogene
- Published
- 2014-01-20
- Volume
- 34
- Issue
- 1
- Pages
- 1-14
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2042012882
- Cited by
- 304
- References
- 173
- FWCI
- 13.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.